amgen
Amgen Faces Investor Lawsuit Over $10.7 Billion Tax Liability
Amgen, investor lawsuit, tax liability, $10.7 billion, legal challenge
Amgen’s Mixed Results: A Tale of Two Readouts in Eczema and Myasthenia Gravis Trials
Amgen, Clinical Trials, Eczema, Myasthenia Gravis, Rocatinlimab, Uplizna, Biotechnology, Pharmaceutical Industry
Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera
Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
FDA Approval of Amgen’s Imdelltra for Lung Cancer Amidst Challenges and Market Competition
Amgen, Imdelltra, FDA approval, lung cancer, bispecific T-cell engager, adverse events, Merck, Curon, Legend Biotech
Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge
Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry
Amgen’s Horizon Acquisition Fuels Revenue Growth and Advances Obesity Drug MariTide
Amgen, Horizon Therapeutics, MariTide, obesity drug, revenue growth, pharmaceutical acquisition
FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer
Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras
Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use
Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody